Strengthera™

Sphaeranthus indicus / Mangifera indica
Evidence Level
Moderate
2 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

Strengthera™ Muscle Maintenance+Vitality is PLT Health Solutions' botanical blend of Sphaeranthus indicus flower head and Mangifera indica stem bark extracts — clinically validated for improving muscle strength, endurance, and physical function specifically in adults aged 55+. The same botanical combination as PLT's RipFACTOR, but studied and positioned for the healthy aging and sarcopenia prevention market.

Studied Dose 650 mg/day; significant results beginning at 4 weeks
Active Compound Sphaeranthus indicus flower head extract + Mangifera indica stem bark extract — Strengthera™ by PLT Health Solutions (650 mg/serving)

Lower body strength improvement

At 12 weeks, the Strengthera cohort showed a 4.2x improvement in lower body strength (1RM leg extension) vs. placebo plus exercise program — a clinically meaningful gain in a population where age-related muscle loss is a primary health concern.

Grip strength and muscle endurance

Subjects taking Strengthera showed a 4.5x improvement in grip strength and a 1.5x improvement in muscle endurance (repetitions to failure at 80% 1RM) vs. placebo at 12 weeks — improvements that translate directly to functional independence and fall prevention.

Walking capacity and functional mobility

An astonishing 90% improvement in walking capacity (6-minute walk test) was observed in the Strengthera group vs. placebo — one of the most meaningful functional outcomes for aging adults and a direct measure of cardiovascular and musculoskeletal health.

mTOR activation and muscle protein synthesis

The proposed mechanism of action includes mTOR pathway activation, inhibition of muscle protein catabolism, mitochondrial efficiency enhancement, and endothelial nitric oxide synthase (eNOS) stimulation — a multi-pathway approach to preserving and building muscle in aging tissue.

1

Mitochondrial efficiency enhancement

Strengthera's primary proposed mechanism is enhancement of mitochondrial energy metabolism efficiency in muscle tissue, making the same amount of exercise more productive and allowing muscle cells to generate more force per ATP consumed.

2

mTOR pathway activation

The botanical combination activates mTOR (mechanistic target of rapamycin), the master regulator of muscle protein synthesis. mTOR activation is required for muscle hypertrophy and is the same pathway stimulated by resistance exercise and leucine.

3

Catabolic inhibition and eNOS stimulation

Strengthera inhibits muscle protein catabolism pathways (reducing proteolysis), while simultaneously stimulating endothelial nitric oxide synthase — improving blood flow and nutrient delivery to working muscle tissue.

1
Strengthera and Muscle Strength in Adults 55+ — RDBPC Trial
PubMed

12-week randomized, double-blind, placebo-controlled study in 92 healthy men and women aged 55–70. Participants received 650 mg/day Strengthera or placebo alongside a standardized at-home exercise program. Assessments at baseline, 4, 8, and 12 weeks.

92 healthy adults aged 55–70. 12-week intervention.

At 4 weeks: significant improvements in lower body and grip strength and muscle endurance. At 12 weeks: 4.2x improvement in lower body strength, 4.5x grip strength improvement, 1.5x muscle endurance improvement, 90% improvement in walking capacity vs. placebo. No serious adverse events.

2
Sphaeranthus indicus/Mangifera indica and Muscle Strength in Young Men — RCT
PubMed

RCT of SMI botanical blend (425 mg and 850 mg/day) vs. placebo in 99 men aged 22±3 performing resistance training for 8 weeks.

99 healthy young men. 8-week resistance training + supplementation protocol.

Both SMI doses significantly augmented bench press and leg extension strength and repetitions-to-failure beyond exercise alone. Testosterone levels increased significantly in supplemented groups. Published in Frontiers in Nutrition, 2024.

Common Potential side effects

Well tolerated across all clinical trials with no serious adverse events reported
Mild GI discomfort possible at initiation
No known contraindications at studied doses

Important Drug interactions

No established drug interactions at current evidence level
Hormone therapies — botanical estrogenic/androgenic activity theoretical; consult physician
mTOR inhibitors (rapamycin, everolimus) — may counteract immunosuppressant mechanism; avoid in transplant patients